Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-0328-2025

BioZorb Marker. Radiographic soft tissue marker. Recall

BioZorb Marker. Radiographic soft tissue marker.

FDA recall Class I

Ongoing

FDA lists this Class I recall for BioZorb Marker. Radiographic soft tissue marker.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-0328-2025
Recall classification
Class I
Enforcement status
Ongoing
Initiation date
Oct 10, 2024
FDA report date
Dec 4, 2024
Quantity in commerce
12,710 units
Distribution
See key details
FDA cause
Device Design

What is being recalled?

BioZorb Marker. Radiographic soft tissue marker.

Affected model & UDI checker

Search the exact identifiers published for Z-0328-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
F0405BioZorb Marker. Radiographic soft tissue marker.Check source noticeNot specified
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514065
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514058
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514041
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514034
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514027
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514010
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045514003
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045513990
Not specifiedBioZorb Marker. Radiographic soft tissue marker.Check source notice15420045513983
FDA code information

Model No. F0405, F0404, F0331, F0231, F0221, F0304, F0303, F0203, F0202; UDI-DI: 15420045514065, 15420045514058, 15420045514041, 15420045514034, 15420045514027, 15420045514010, 15420045514003, 15420045513990, 15420045513983; Lot No. 22E24RH, 23A09RK, 23L23RP, 22E24RG, 23A09RJ, 23E03R, 23G28RW, 22F06RL, 22G26RQ, 22K25RA, 23A09RH, 23A30RP, 23C02RJ, 23H25RW, 23K04RC, 23K31RG, 24A30RG, 22D21RBB, 22F06RK, 22F29RK, 22G26RP, 22H24RM, 22J26RG, 22K25R, 22L22R, 22M20RM, 23A26RV, 23C02RH, 23E27RF, 23F29RT, 23H03R, 23H25RU, 23K04RA, 23L23RK, 24B02RD, 24B27RK, 22D21RAA, 22E24RA, 22F29RJ, 22G26RN, 22H24RL, 22J26RF, 22K21R, 22L22RA, 22M20RL, 23A26RU, 23C02RG, 23C30RQ, 23E03RA, 23F29RP, 23G28RV, 23H25RV, 23K02RB, 23K31RD, 23L23RH, 24A08RY, 24B01R, 24B27RL, 24C22RN, 22D21RZ, 22E24RB, 22F25RF, 22G26RM, 22H24RK, 22J26RD, 22K19RW, 22L22RB, 23C02RK, 23E25RY, 23F29RS, 23H24RP, 23K04RB, 23K31RF, 23L23RJ, 22D21RY, 22E24R, 22F25RD, 22G26RL, 22H22RT, 22J26RC, 22K19RV, 22L22RC, 23A09RN, 23H03RA, 23H31R, 23K04RD, 23K25RM, 22D21RX, 22E20RAA, 22F21R, 22G21RM, 22H22RS, 22J22RBB, 22K19RU, 22L22RF, 23A09RM, 23A30RQ, 23B24RZ, 23C30RP, 23D27RJ, 23E31RD, 23F28RZ, 23G31RJ, 23H24RQ, 23K02RA, 23K25RN, 22D20RV, 22E20RZ, 22F16RV, 22G21RL, 22H20R, 22J22RAA, 22K19RT, 22K25RB, 22L22RD, 23A09RL, 23B24RY, 23C28RJ, 23D27RH, 23E30RF, 23F29RQ, 23G31RH, 23H24RN, 23K02R, 23K25RL.

View the original FDA recall notice

Why was this product recalled?

Firm received reports of adverse events/complications that include serious injuries, such as pain, infection, rash, device migration, device erosion, seroma, and discomfort.

What actions did Hologic, Inc. take?

Consignees were sent an URGENT: MEDICAL DEVICE RECALL letter by mail dated 10/24/24. The notification instructs consignees to quarantine all affected devices and share the recall notification with all surgeons in their practice that have used or planned to use the BioZorb Marker. Additionally, if product was further distributed the notice is to be forwarded to those customers. Affected devices will be returned to Hologic and coordination of return will be initiated by return of the Customer Response Form. Healthcare providers are recommended to be aware of reports of serious adverse events following the placement of the BioZorb Marker devices in breast tissue and to continue to monitor patients for signs of any adverse events. BioZorb Markers are not cleared to fill space in the tissue or improve cosmetic outcomes after procedures. Patients are recommended to contact their healthcare provider if they experience any adverse events following the placement of their BioZorb marker. Hologic states that there is no need to undergo explantation of the device unless advised by your healthcare provider. Patients who have received the BioZorb Marker and/or your provider is planning radiation therapy treatments, discuss the possible risks with your provider. Report any problems/complications and direct any questions regarding this recall to Hologic at [email protected]. ***Update May 5, 2026: On April 6, 2026 A Follow-up notification as an updated resource for clinicians who have previously used Biozorb breast markers or are currently caring for patients implanted with BioZorb markers. Hologic recalled and removed from market BioZorb and BioZorb LP on October 24, 2024; therefore, all patients with these implants have had them in place for at least one year. The original notification that was distributed as a part of the previous recall can be found as an appendix to this resource.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology